Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Advanced Solid TumorsExcluding Breast Cancer
Interventions
DRUG

TKI258

Trial Locations (14)

10467

Montefiore Medical Center Montefiore Medical Center (SC), The Bronx

33901

Florida Cancer Specialists Sarasota Office, Fort Myers

37203

Sarah Cannon Research Institute Sarah Cannon Research (SC), Nashville

53792

University of Wisconsin Univ Wisc, Madison

60612

Rush University Medical Center Rush 3, Chicago

63110

Washington University School of Medicine SC, St Louis

73104

University of Oklahoma Health Sciences Center OUHSC - SC, Oklahoma City

78229

Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5), San Antonio

78246

Sammons Cancer Center - Texas Oncology SC-2, Dallas

84112

University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City

90095

University of California at Los Angeles UCLA LeConte Location, Los Angeles

94101

University of California San Francisco UCSF (SC), San Francisco

91010-3000

City of Hope National Medical Center SC-2, Duarte

15232-1305

University of Pittsburgh Cancer Institute, Pittsburgh

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY